Companies › SNGX
Soligenix Inc (SNGX)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0000812796 · EDGAR filings · Updated 2026-07-23
Soligenix Inc (SNGX) has reported institutional ownership of 2.5%, with 15 institutional managers holding positions valued at $307.4K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Filings this week (1)
- 2026-07-23 — PRER14A filed
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Latest updates
- 2026-07-21 — PRE 14A filed
- 2026-06-26 — Current report (8-K) filed
- 2026-06-26 — Prospectus supplement (424B5) filed
- 2026-06-25 — SCHEDULE 13G filed
- 2026-06-12 — Current report (8-K) filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, Soligenix Inc has 15 institutional holders and institutional ownership of 2.5%.
Insider activity
Insiders reported 1 transactions (1 buys, 0 sells) across 1 reporting insiders, with a net reported value of $20.0K.
Data flags from SEC filings
Related companies
MOLECULIN BIOTECH INC (MBRX) · KAIROS PHARMA LTD (KAPA) · NexGel Inc (NXGL) · Akari Therapeutics PLC ADR (AKTX) · Nuwellis Inc (NUWE) · MANGOCEUTICALS INC (MGRX)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-23.